Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
1,052. 20
+30.18
+2.95%
$
970.55B Market Cap
104.2 P/E Ratio
6% Div Yield
2,455,171 Volume
6.64 Eps
$ 1,022.02
Previous Close
Day Range
1,017.36 1,052.83
Year Range
623.78 1,133.95
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LLY earnings report is expected in 59 days (29 Apr 2026)
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today

If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today

Eli Lilly has gained attention in recent time thanks to its weight-loss drugs. Demand for these products is driving revenue higher.

Fool | 1 year ago
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.

Zacks | 1 year ago
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

Zacks | 1 year ago
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.

Fool | 1 year ago
Eli Lilly Gets Green Light to Sell Weight-Loss Drug in China

Eli Lilly Gets Green Light to Sell Weight-Loss Drug in China

Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.

Investopedia | 1 year ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Eli Lilly's weight loss drug tirzepatide gets approval in China

Eli Lilly's weight loss drug tirzepatide gets approval in China

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the key Asian market.

Reuters | 1 year ago
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Since the start of 2020, Eli Lilly's ( NYSE: LLY ) stock price chart  has been straight up and to the right, up 553% and currently trading at $848.74.

247wallst | 1 year ago
Eli Lilly's stock plunges as investors eye obesity-drug competition

Eli Lilly's stock plunges as investors eye obesity-drug competition

Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.

Marketwatch | 1 year ago
Will Eli Lilly Do a Stock Split in 2024?

Will Eli Lilly Do a Stock Split in 2024?

Eli Lilly's surging valuation has made the case for a stock split. Many growth stocks have deployed stock splits in recent years, including Eli Lilly rival Novo Nordisk.

Fool | 1 year ago
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

Eli Lilly (LLY) concluded the recent trading session at $941.60, signifying a -0.93% move from its prior day's close.

Zacks | 1 year ago
3 Biotech Stocks to Buy in Case of Another Pandemic

3 Biotech Stocks to Buy in Case of Another Pandemic

While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics. This is admittedly a concerning and uncomfortable thought, considering the severe societal damage that occurred as a result of the Covid-19 pandemic.

Investorplace | 1 year ago
Loading...
Load More